Rolipram

12/01/2001 - "Taken together, these results might explain why certain cAMP-elevating agents such as rolipram are effective in blocking autoimmunity and inflammation."
02/01/2023 - "In addition, rolipram treatment reduced inflammation, which was characterized by a decrease in macrophage accumulation and reduced levels of CCL2 and TNF in the kidneys. "
01/01/2018 - "Rolipram reduced adipose deposition and inflammation and reserved metabolic disorder. "
01/01/2016 - "Rolipram could suppress the inflammatory signals and could be a potential therapeutic strategy against LPS-induced inflammation to protect the salivary gland cells. "
01/04/2013 - "Although rolipram is well known to reduce pathology and inflammation in several other CNS injury models, the pathology resulting from CCI was worsened with rolipram at this particular dose and administration schedule. "

08/01/1996 - "Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats."
11/01/2005 - "Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS). "
10/01/2009 - "We conclude that the reasons underlying the discrepancy between the therapeutic efficacy of rolipram in experimental autoimmune encephalomyelitis versus multiple sclerosis are at present not clear."
10/01/2009 - "Rolipram, a prototypic phosphodiesterase-4 inhibitor, is highly effective in suppressing Th1 autoimmunity in multiple animal models, including experimental autoimmune encephalomyelitis. "
12/01/2008 - "Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis."

04/01/2017 - "Rolipram treatment significantly attenuated STZ induced and age related memory deficits, biochemical and histopathological alterations. "
06/01/2007 - "Rolipram (0.1 mg/kg) reversed the memory deficit induced by ATD in a dose-dependent manner. "
06/01/2007 - "The effect of rolipram (0, 0.01, 0.03, and 0.1 mg/kg, i.p.) was tested in the condition in which ATD induced a clear memory deficit. "
12/01/2004 - "One course of long-term systemic treatment with rolipram improves LTP and basal synaptic transmission as well as working, reference, and associative memory deficits for at least 2 months after the end of the treatment. "
01/01/2023 - "Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling."

10/11/2023 - "Correction to: Rolipram and pentoxifylline combination ameliorates experimental diabetic neuropathy through inhibition of oxidative stress and inflammatory pathways in the dorsal root ganglion neurons."
10/01/2022 - "Rolipram and pentoxifylline combination ameliorates experimental diabetic neuropathy through inhibition of oxidative stress and inflammatory pathways in the dorsal root ganglion neurons."
11/01/2023 - "Rolipram and pentoxifylline combination ameliorates the morphological abnormalities of dorsal root ganglion neurons in experimental diabetic neuropathy by reducing mitochondrial dysfunction and apoptosis."

07/01/2012 - "This study suggests that rolipram might alleviate mechanical allodynia induced by alcohol in rats, which clearly has clinical implication."
09/01/2015 - "These results suggest that rolipram alleviated mechanical allodynia induced by PAC in rats. "
07/17/2006 - "It is well known that rolipram locally administered induces some adverse effects such as hyperalgesia. "
07/07/2000 - "Pretreatment with rolipram abrogated oedema formation and significantly inhibited hyperalgesia. "
07/01/2012 - "The mechanical allodynia, which began to manifest on the 3 weeks, intraperitoneal injections of rolipram sustained statistical difference until 8 weeks, the final week of the study (p<0.05). "